Although there is an obvious rationale for inhibiting EZH2 function in malignancies in which this gene is overactivated, the finding of inactivating mutations in myeloid neoplasms suggests that this approach will need to be employed with caution. The gene discussed is EZH2; the disease is myeloid neoplasm.